Economics in sample size determination for clinical trials

other OA: closed public-domain-us
View on PubMed View at publisher

Abstract

In the design of clinical trials, sample size determination is usually undertaken by statisticians and clinicians. It is rare for health economists to be involved in this aspect of trial design. However, there are a number of outcome changes that are of 'economic significance', and it is important for trial designers and funders to be aware of these before planning, funding and mounting a trial. In this paper we demonstrate through the use of three examples (prevention of osteoporosis, management of infertility, and endometriosis) how economics can be used to influence the size of a clinical trial. Trials that are too small or too large waste research resources; health economics can lead to more efficient trial designs.

My notes (saved in your browser only)

Condition tags

endometriosisinfertility

MeSH descriptors

Clinical Trials as Topic Sample Size Adult Aged Clinical Trials as Topic Cost-Benefit Analysis Danazol Danazol Endometriosis Endometriosis Female Goserelin Goserelin Humans Hydrochlorothiazide Hydrochlorothiazide Infertility, Female Infertility, Female Osteoporosis Osteoporosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-06-21T06:12:49.409960+00:00
pubmed
last seen: 2026-05-13T22:11:13.665691+00:00
unpaywall
last seen: 2026-05-16T02:00:00.672124+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine